vorinostat Articles
Five new drugs for myelodysplastic syndromes set to launch by 2018
10 February 2013
More news briefs from ASH meeting
14 December 2011
Taiho to market Merck & Co’s CTLC drug vorinostat in Japan, where MSD is expelled from JPMA
17 June 2011
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
3 February 2010
MSD withdraws MA for vorinostat in EU
23 February 2009
Zolinza/Velcade combo enters Ph IIb MM trial
26 January 2009
$1M Merck & Co research grant for NCCN
8 December 2008
Merck & Co files MAA for vorinostat in CTCL
3 December 2007
Japanese study group urges Zolinza appro
7 May 2007
Japan's MHLW proposes "drug lag" solution
5 February 2007
Merck & Co gets FDA approval for Zolina
16 October 2006
Merck & Co's Zolina accepted for review by FDA
19 June 2006
Showing 1-16 of 16 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
